Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin beta-8 (PCDHB8) is a member of the protocadherin beta gene cluster within the cadherin superfamily of cell-adhesion molecules[1][7]. It is an integral plasma membrane protein with six extracellular cadherin domains and a unique cytoplasmic tail[1][7]. PCDHB8 participates in calcium-dependent homophilic (same-protein) cell-cell interactions, which are thought to regulate neuronal self-recognition and the formation of specific neuronal circuits in the developing brain[1][6][7]. While PCDHB8's detailed functional role is not well characterized, it is implicated in the establishment and maintenance of neural connections rather than being a direct mediator of signal transduction or a known therapeutic target[1][6][7]. There are no known small-molecule or biological therapeutics modulating PCDHB8, nor is it used as a clinical biomarker. Variants have been associated with certain rare developmental disorders, but causality and clinical significance are not established[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protocadherin beta-8 (PCDHB8).